New-onset or flare-up of bullous pemphigoid associated with COVID-19 vaccines: a systematic review of case report and case series studies
BackgroundNumerous cutaneous manifestations have been associated with the Coronavirus Disease 2019 (COVID-19) outbreak and vaccination, but new-onset bullous pemphigoid (BP) or flaring up of pre-existing BP is a rare side effect of COVID-19 vaccines that has been mentioned to a lesser extent in the literature. Therefore, we aimed to conduct a systematic review focused on the association between the new- onset or flare-up of BP and the COVID-19 vaccination.MethodA comprehensive literature search was conducted using PubMed (MEDLINE), Scopus, and the Web of Science databases up to 11 March 2023. The search aimed to identify English-language studies reporting new-onset or flare-ups of BP as a potential side effect of the COVID-19 vaccination. The search terms included bullous pemphigoid and COVID-19 vaccination-related MeSH terms.ResultsThe systematic review of 40 articles investigating the incidence of BP in individuals who received various COVID-19 vaccines revealed pertinent findings. Among the 54 patients with new-onset BP, the median age was 72.42 years, and most were men (64%). Conversely, the median age of the 17 patients experiencing a flare-up of BP was 73.35 years, with a higher proportion of women (53%). Regarding vaccination types, a significant number of patients (56%) developed new-onset BP after receiving the BNT162b2 vaccine (Pfizer-BioNTech).ConclusionThis study indicates a potential association between COVID-19 vaccinations, particularly mRNA vaccines, and the occurrence of BP. It suggests that this rare autoimmune disorder may be triggered as an adverse event following the COVID-19 vaccination. However, it is important to note that the majority of BP patients in our study were unaffected by the COVID-19 vaccine, and even those who experienced worsening of their conditions were managed without significant consequences. These findings provide additional evidence supporting the safety of COVID-19 vaccines. Physicians should be mindful of this uncommon adverse event and encourage patients to complete their planned vaccination schedules..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Frontiers in Medicine - 11(2024) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aref Ghanaatpisheh [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Bullous pemphigoid |
|---|
| doi: |
10.3389/fmed.2024.1293920 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ091474132 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ091474132 | ||
| 003 | DE-627 | ||
| 005 | 20240412093615.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fmed.2024.1293920 |2 doi | |
| 035 | |a (DE-627)DOAJ091474132 | ||
| 035 | |a (DE-599)DOAJ4b8a8bf24304470a965032cffda8c336 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a R5-920 | |
| 100 | 0 | |a Aref Ghanaatpisheh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New-onset or flare-up of bullous pemphigoid associated with COVID-19 vaccines: a systematic review of case report and case series studies |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a BackgroundNumerous cutaneous manifestations have been associated with the Coronavirus Disease 2019 (COVID-19) outbreak and vaccination, but new-onset bullous pemphigoid (BP) or flaring up of pre-existing BP is a rare side effect of COVID-19 vaccines that has been mentioned to a lesser extent in the literature. Therefore, we aimed to conduct a systematic review focused on the association between the new- onset or flare-up of BP and the COVID-19 vaccination.MethodA comprehensive literature search was conducted using PubMed (MEDLINE), Scopus, and the Web of Science databases up to 11 March 2023. The search aimed to identify English-language studies reporting new-onset or flare-ups of BP as a potential side effect of the COVID-19 vaccination. The search terms included bullous pemphigoid and COVID-19 vaccination-related MeSH terms.ResultsThe systematic review of 40 articles investigating the incidence of BP in individuals who received various COVID-19 vaccines revealed pertinent findings. Among the 54 patients with new-onset BP, the median age was 72.42 years, and most were men (64%). Conversely, the median age of the 17 patients experiencing a flare-up of BP was 73.35 years, with a higher proportion of women (53%). Regarding vaccination types, a significant number of patients (56%) developed new-onset BP after receiving the BNT162b2 vaccine (Pfizer-BioNTech).ConclusionThis study indicates a potential association between COVID-19 vaccinations, particularly mRNA vaccines, and the occurrence of BP. It suggests that this rare autoimmune disorder may be triggered as an adverse event following the COVID-19 vaccination. However, it is important to note that the majority of BP patients in our study were unaffected by the COVID-19 vaccine, and even those who experienced worsening of their conditions were managed without significant consequences. These findings provide additional evidence supporting the safety of COVID-19 vaccines. Physicians should be mindful of this uncommon adverse event and encourage patients to complete their planned vaccination schedules. | ||
| 650 | 4 | |a bullous pemphigoid | |
| 650 | 4 | |a COVID-19 vaccines | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a flare-up | |
| 650 | 4 | |a new-onset | |
| 653 | 0 | |a Medicine (General) | |
| 700 | 0 | |a Mohadesseh Safari |e verfasserin |4 aut | |
| 700 | 0 | |a Hoda Haghshenas |e verfasserin |4 aut | |
| 700 | 0 | |a Ali Motamed-Sanaye |e verfasserin |4 aut | |
| 700 | 0 | |a Ali Motamed-Sanaye |e verfasserin |4 aut | |
| 700 | 0 | |a Amir Homayoun Atefi |e verfasserin |4 aut | |
| 700 | 0 | |a Karo Kamangarpour |e verfasserin |4 aut | |
| 700 | 0 | |a Mohammad Aref Bagherzadeh |e verfasserin |4 aut | |
| 700 | 0 | |a Amirhossein Kamran-Jahromi |e verfasserin |4 aut | |
| 700 | 0 | |a Mohammad Darayesh |e verfasserin |4 aut | |
| 700 | 0 | |a Navid Kouhro |e verfasserin |4 aut | |
| 700 | 0 | |a Amir Reza Bahadori |e verfasserin |4 aut | |
| 700 | 0 | |a Mohammad Ali Esfandiari |e verfasserin |4 aut | |
| 700 | 0 | |a Mohammad Ali Esfandiari |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Medicine |d Frontiers Media S.A., 2014 |g 11(2024) |w (DE-627)DOAJ000022292 |x 2296858X |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2024 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fmed.2024.1293920 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/4b8a8bf24304470a965032cffda8c336 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fmed.2024.1293920/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2296-858X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2024 | ||